Insomnia is the sustained difficulty falling asleep, staying asleep, or waking too early with a feeling of insufficient rest, accompanied by daytime consequences (fatigue, irritability, difficulty concentrating, sleepiness, impaired functio… Read more.
41 factors with evidence, ordered from most to least effective. Information, not medical advice.
*⏱ 2 min read
Most people understand the importance of sleep duration, but there is another critical and frequently ignored factor that plays a fundamental role in health and performance: sleep regularity, which is not just how much you sleep but how consistently you go to bed and get up each day; a growing body of research suggests that erratic sleep schedules, with inconsistent bedtimes, wake times, and durations, can have profound consequences for physical and mental health.
Irregular sleep patterns have been linked to metabolic dysfunction, cardiovascular disease, mood disorders, riskier behaviors, and cognitive decline; studies indicate that keeping a consistent sleep schedule may be as important as getting enough sleep, if not more so; an especially striking finding is that sleep variability, especially inconsistent wake times, may predict negative health outcomes more strongly than total sleep duration.
People with very irregular sleep patterns have a 26% higher risk of heart attack, heart failure, and stroke compared with the most consistent sleepers, and among moderately irregular sleepers the risk of cardiovascular events rises by 8%; even more concerning, an inconsistent sleep pattern raises cardiovascular risk even in people with sufficient sleep duration, meaning that getting enough sleep does not offset the negative effects of an irregular sleep pattern.
An experiment that shifted sleep and meal times by 5 hours for 5 days, holding sleep duration and diet constant, found that after just one day of eating later than usual, participants experienced a 90-minute delay in gastric emptying, glucose and triglyceride levels rose significantly after meals, and sleepiness and alertness levels were continuously impaired through the fifth day of the altered schedule, even though the metabolic response improved around the third day.
⏱ 3 min read
Insomnia is the persistent difficulty falling asleep, staying asleep, or waking too early with a feeling of insufficient rest, accompanied by daytime consequences (fatigue, irritability, difficulty concentrating, sleepiness, impaired social or occupational functioning); it affects between 10% and 30% of the adult population at some point during the year and approximately 10% chronically; it is one of the most frequent reasons for consultation in primary care and one of the main reasons for the use (and overuse) of hypnotic medication. The good news is that first-line treatment is not pharmacological but behavioral (CBT-I), with greater and more sustained efficacy than drugs.
Cognitive behavioral therapy for insomnia (CBT-I) is the treatment with the best evidence and the best risk-benefit ratio for chronic insomnia, recommended as first line by all international clinical guidelines (American College of Physicians, European Sleep Research Society, NICE):
Sustained efficacy superior to hypnotics in the long term, with no adverse effects or dependence. Available in person, in groups, or via validated digital apps (Sleepio, CBT-I Coach).
Melatonin (0.5-3 mg, 30-60 min before bedtime): especially useful in circadian misalignment (jet lag, shift work, phase delay) and in older adults with reduced endogenous levels. Low doses are usually more effective than high ones. Extended-release is useful in sleep-maintenance insomnia.
Glycine (3 g before bedtime): improves subjective sleep quality and lowers core body temperature.
Magnesium (200-400 mg glycinate or malate): especially useful in subclinical deficiency.
L-theanine (200 mg): promotes relaxation before bed.
Tryptophan (1-3 g): precursor of serotonin and melatonin.
Valerian: modest support.
Passionflower: modest support, especially with associated anxiety.
Apigenin (chamomile): mild GABAergic effects.
Benzodiazepines (lormetazepam, lorazepam, diazepam) and Z-drugs (zolpidem, zopiclone, zaleplon) are effective in the short term but carry a risk of dependence, tolerance, rebound insomnia on discontinuation, residual morning sedation, falls, and cognitive impairment in older adults. They should not be used chronically if there are alternatives (CBT-I). If they are used, short (2-4 weeks) and intermittent courses are preferable. Other drugs with a hypnotic profile (mirtazapine, trazodone, sedating antihistamines) have specific indications and must be prescribed carefully.
Insomnia is best treated by addressing causes (hygiene, habits, comorbidities) and with CBT-I as first line for chronic cases; mild supplements (melatonin, glycine, magnesium) are useful add-ons; pharmacological hypnotics have a place in acute situations or when other options fail, but they are not a sustainable solution for chronic insomnia.
⏱ 3 min read
Insomnia is the persistent difficulty falling asleep, staying asleep, or waking too early with a feeling of insufficient rest, accompanied by daytime consequences (fatigue, irritability, difficulty concentrating, sleepiness, impaired social or occupational functioning); it affects between 10% and 30% of the adult population at some point during the year and approximately 10% chronically; it is one of the most frequent reasons for consultation in primary care and one of the main reasons for the use (and overuse) of hypnotic medication. The good news is that first-line treatment is not pharmacological but behavioral (CBT-I), with greater and more sustained efficacy than drugs.
Cognitive behavioral therapy for insomnia (CBT-I) is the treatment with the best evidence and the best risk-benefit ratio for chronic insomnia, recommended as first line by all international clinical guidelines (American College of Physicians, European Sleep Research Society, NICE):
Sustained efficacy superior to hypnotics in the long term, with no adverse effects or dependence. Available in person, in groups, or via validated digital apps (Sleepio, CBT-I Coach).
Melatonin (0.5-3 mg, 30-60 min before bedtime): especially useful in circadian misalignment (jet lag, shift work, phase delay) and in older adults with reduced endogenous levels. Low doses are usually more effective than high ones. Extended-release is useful in sleep-maintenance insomnia.
Glycine (3 g before bedtime): improves subjective sleep quality and lowers core body temperature.
Magnesium (200-400 mg glycinate or malate): especially useful in subclinical deficiency.
L-theanine (200 mg): promotes relaxation before bed.
Tryptophan (1-3 g): precursor of serotonin and melatonin.
Valerian: modest support.
Passionflower: modest support, especially with associated anxiety.
Apigenin (chamomile): mild GABAergic effects.
Benzodiazepines (lormetazepam, lorazepam, diazepam) and Z-drugs (zolpidem, zopiclone, zaleplon) are effective in the short term but carry a risk of dependence, tolerance, rebound insomnia on discontinuation, residual morning sedation, falls, and cognitive impairment in older adults. They should not be used chronically if there are alternatives (CBT-I). If they are used, short (2-4 weeks) and intermittent courses are preferable. Other drugs with a hypnotic profile (mirtazapine, trazodone, sedating antihistamines) have specific indications and must be prescribed carefully.
Insomnia is best treated by addressing causes (hygiene, habits, comorbidities) and with CBT-I as first line for chronic cases; mild supplements (melatonin, glycine, magnesium) are useful add-ons; pharmacological hypnotics have a place in acute situations or when other options fail, but they are not a sustainable solution for chronic insomnia.